A single-site study of the effectiveness of Dapagliflozin for diabetic patients admitted to the intensive care unit
- Conditions
- DiabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12621001102864
- Lead Sponsor
- Austin Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Adult aged 18 years or greater
Expected to be admitted to the ICU until the day after tomorrow
Pre-existing diagnosis of Type-2 diabetes mellitus
Estimated Glomerular Filtration rate (eGFR) of less than 45 ml/min/1.73m2
Able to take medication enterically
Diagnosis of Type-1 diabetes mellitus (T1DM)
Documented SGLT2 inhibitor intolerance
Hepatic impairment with aspartate transaminase [AST] or alanine transaminase [ALT] greater than 3x the upper limit of normal [ULN]; or total bilirubin greater than 2x ULN at time of enrolment
No enteric route for medication administration
Pregnancy
Death is deemed to be imminent or inevitable during this admission
Patients with diabetic ketoacidosis
Pre-existing urinary tract infection
Hypernatraemia defined as a serum sodium levels equal to or greater than 150 mmol/L at the time of screening
Clinician deems enrolment in the study is not in the patient’s best interests
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method